467 |
Addressing the Controversy of Late DES Thrombosis |
Martin Bert Leon |
Oct. 05. 07 |
466 |
IVUS Roles and Benefits in DES Era |
Seung-Jea Tahk |
Oct. 05. 07 |
465 |
TAXUS Clinical Result Updates & Future Pipeline |
Joerg Koglin |
Oct. 05. 07 |
464 |
Bifurcations and Left Main with TAXUS |
Thierry Lefevre |
Oct. 05. 07 |
463 |
Better Diabetic Performance in TAXUS |
Antonio Colombo |
Oct. 05. 07 |
462 |
The Science Behind Xience V |
Jacques J. Koolen |
Sep. 28. 07 |
461 |
SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent) |
Gregg W. Stone |
Sep. 28. 07 |
460 |
DES Safety Concerns: Impact on Clinical Practice |
Martin Bert Leon |
Sep. 28. 07 |
459 |
What Makes Endeavor Different |
Alan C. Yeung |
Sep. 28. 07 |
458 |
Endeavor - Combining Safety with Efficacy |
Eulogio Garcia |
Sep. 28. 07 |